MedPath

Study of Vonoprazan-based triple theary for eradication of helicobacter pylori

Not Applicable
Conditions
gastritis with helicobacter pylori infection
Registration Number
JPRN-UMIN000022846
Lead Sponsor
Onaka Clinic
Brief Summary

The success rate of vonoprazan-based triple thearpy was 91.7% at the primary eradication compare to 80.9% with PPI. It is significant better result.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
2000
Inclusion Criteria

Not provided

Exclusion Criteria

none

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Success rate of the eradication therapy after one month later by urea breath test
Secondary Outcome Measures
NameTimeMethod
Mortality and morbidity of the eradication therapy
© Copyright 2025. All Rights Reserved by MedPath